In situ forming depots based on RESOMER LC 703 S, a random 70:30 L-lactide/ε-caprolactone copolymer with nominal inherent viscosity of 0.7 dL/g (chloroform, 25 °C, c=0.1 g/dL), are prepared by dissolving the polymer in N-methyl-2-pyrrolidone (NMP) at polymer concentrations of 30–45% w/w together with a lipophilic peptide or low-molecular-weight drug substance. The formulated solution is filtered through a 0.22 µm PVDF membrane and filled into presterilized glass syringes under Grade A laminar airflow. Upon contact with subcutaneous fluid, the water-miscible solvent exchanges with water and the polymer precipitates as a solid implant with a porous inner core; the initial burst release is governed by the solvent efflux rate and the drug diffusion coefficient in the water-rich boundary layer, while the subsequent release phase is dominated by bulk hydrolysis of the ε-caprolactone segments. Residual NMP must comply with ICH Q3C Class 2 permitted daily exposure of 53 mg/day, and the final implant is assessed under ISO 10993-1, ISO 10993-5, ISO 10993-10, USP <85> bacterial endotoxin, and USP <788> subvisible particulate matter. Terminal sterilization by gamma irradiation at 25 kGy often reduces the inherent viscosity of lactide-caprolactone copolymers by 10–20%; published data for this specific grade under 25 kGy is limited, so aseptic filtration of the non-thermoplastic solution is preferred when the drug substance is heat-labile. The end product is a single-use prefilled depot syringe, with implant persistence in vivo of 3–6 months depending on the lactide-to-caprolactone ratio, implant surface area, and injection volume.

What Encapsulation Variables Shift the Dv50 of LC 703 S Microspheres into the 20–60 µm Range?

A water-in-oil-in-water (W/O/W) double emulsion route is used for hydrophilic peptide salts that would partition poorly into a single oil phase. The inner water phase, containing the peptide at 50–100 mg/mL in pH 4.0 acetate buffer, is emulsified into a dichloromethane solution of RESOMER LC 703 S at 5–10% w/w using a rotor-stator homogenizer at 8,000–12,000 rpm for 2 min. The primary emulsion is then dispersed into an external aqueous phase containing 1.0% w/v polyvinyl alcohol (PVA, 87–89% hydrolyzed) and 0.5% w/v sodium chloride to reduce drug diffusion, with a second homogenization step at 6,000–10,000 rpm for 3 min. The resulting microspheres are hardened by solvent evaporation under atmospheric stirring at 25 °C for 4 h, washed with water for injection, and lyophilized to a residual moisture content below 0.5% by Karl Fischer. Particle size distribution is measured by laser diffraction per ISO 13320:2020, with target Dv50 between 20 µm and 60 µm for syringeability through 23G needles. Encapsulation efficiency varies inversely with the inner water phase volume and the duration of the second homogenization, while surface porosity and initial burst release increase when the dichloromethane removal rate exceeds 1.0 g/min/kg of batch volume. Residual dichloromethane is controlled to ≤600 ppm per USP <467> Option I, and the finished microspheres are evaluated by USP <790> visible particulates, USP <85> endotoxin, and ISO 10993-6 for implantation histology. End product is a lyophilized microsphere powder for reconstitution in a viscous diluent, with sustained release over 30–90 days after intramuscular or subcutaneous injection.

Prior to melt extrusion into monofilament suture, RESOMER LC 703 S granules are vacuum-dried at 40 °C and below 10 mbar for 16 h until moisture by Karl Fischer is below 0.05 wt%. A single-screw extruder with 20:1 L/D, 14 mm screw diameter, and a metering section compression ratio of 2.5:1 is run at barrel zone set points of 125 °C, 135 °C, 145 °C, and die temperature 140 °C; screw speed is kept at 15–25 rpm to limit shear heating. The extrudate is quenched in water at 10–15 °C, then drawn in two stages at 55–65 °C with a total draw ratio of 4:1 to 5:1, and annealed at 70 °C under nitrogen for 12 h. Draw ratios above 5:1 produce surface fibrillation and knot-pull strength failures in size 2-0 monofilaments because the caprolactone-rich amorphous phase has low strain-hardening reserve at this viscosity. Tensile properties are measured on conditioned specimens per ASTM D638-14 Type V and must exceed 300 MPa ultimate tensile stress with elongation at break above 30% after sterilization; knot-pull strength is tested per USP <881>. The suture is sterilized by ethylene oxide, and residuals must comply with ISO 10993-7. Degradation in phosphate-buffered saline at 37 °C is evaluated according to ASTM F1635-16, with tensile strength retention above 50% at 14 days as the acceptance criterion. The end product is an absorbable monofilament suture for soft tissue approximation, packaged with moisture-impermeable foil and desiccant to maintain the pre-dried state during storage.

When LC 703 S Sheets Are Compression-Molded below 10 MPa, Why Does Cooling Rate Control Pinhole Formation?

Pre-dried granules are placed between polyimide release films in a hydraulic press with heated platens set to 135 °C and 145 °C. The polymer is melted under 0.5 MPa contact pressure for 3 min, then compressed at 8 MPa for 5 min, followed by cooling to 25 °C at 2 °C/min while pressure is maintained. Fast cooling above 5 °C/min traps microvoids in the caprolactone-rich domains because the bulk vitrification temperature of the 70:30 lactide-caprolactone copolymer is near 20 °C and the melt has insufficient time to relax stress at the platen-sample interface. Pinhole defects are detected by a voltage discharge tester at 1.5 kV over the film surface; the acceptance criterion is zero pinholes per 100 cm². Film thickness is controlled between 100 µm and 200 µm with a machined steel shim, and tensile properties are measured per ISO 527-3:2018, with tensile strength normally above 25 MPa and elongation above 250%. In vitro degradation in pH 7.4 phosphate-buffered saline at 37 °C follows ISO 13781:2017, recording inherent viscosity loss, mass loss, and pH changes at 1, 4, 8, 16, 26, 39, and 52 weeks. Biological evaluation for an absorbable anti-adhesion film includes ISO 10993-5 cytotoxicity, ISO 10993-10 skin sensitization, and ISO 10993-6 implantation testing in a rodent model. The end product is a translucent, flexible film intended for temporary separation of tendon or peritoneal surfaces, where the low melting temperature of the grade allows shaping under warm saline at the surgical site.

Electrospun Tubular Conduits for Peripheral Nerve Gap Repair

RESOMER LC 703 S is dissolved in 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) at 10% w/v or in a 3:1 v/v chloroform/dimethylformamide mixture at 8–12% w/v. The solution is loaded into a syringe pump and dispensed through a 22G blunt stainless steel needle at 0.8–1.5 mL/h, while a high-voltage supply applies 12–18 kV to the needle tip relative to a grounded aluminum mandrel rotating at 500–1,000 rpm. The mandrel-to-needle distance is maintained at 150–200 mm, and the relative humidity is controlled below 40% to prevent phase separation induced by water vapor. Fiber diameter, measured by scanning electron microscopy and image analysis, falls between 400 nm and 1.2 µm depending on solution conductivity and solvent volatility. The mat is cut into strips and wrapped around a 1.5 mm diameter polytetrafluoroethylene mandrel to create a conduit with wall thickness 0.2–0.4 mm. Mechanical properties are tested per ASTM D882-18 on flat specimens; radial tensile strength must exceed 2.0 N measured by the method described in ASTM F2902-16. Residual HFIP is controlled to the limit specified in ICH Q3C for solvents with no adequate toxicological data; due to limited published toxicity data for HFIP, many manufacturers replace it with chloroform/dimethylformamide despite slower evaporation. The inner surface is coated with laminin or poly-D-lysine at 10 µg/cm² to promote Schwann cell adhesion, and the device is sterilized by ethylene oxide per ISO 11135:2014. The end product is a flexible nerve conduit with a compressive modulus that resists collapse during flexion, indicated for gaps up to 10 mm in rat models; published data for human peripheral nerve gaps with this specific polymer grade remains limited.

Using supercritical carbon dioxide as a plasticizing foaming agent, porous scaffolds are produced by equilibrating compression-molded RESOMER LC 703 S disks in a high-pressure view cell at 50 °C and 15 MPa for 4 h, followed by controlled depressurization at 0.2 MPa/min. The caprolactone-rich domains plasticize preferentially because carbon dioxide solubility in the amorphous phase exceeds that in the semicrystalline lactide segments; the resulting pore diameter measured by mercury porosimetry ranges from 50 µm to 250 µm, with total porosity between 60% and 80% when the decompression rate is reduced below 0.5 MPa/min. Pore interconnectivity is confirmed by scanning electron microscopy and by permeation of phosphate-buffered saline under 10 kPa hydrostatic head. The scaffold is washed in supercritical carbon dioxide at 40 °C and 20 MPa for 2 h to remove residual solvents and low-molecular-weight fractions, then dried under vacuum at 30 °C for 24 h. Mechanical testing per ASTM D1621-16 for compressive modulus and ASTM D638-14 for tensile properties provides an initial compressive modulus of 5–20 MPa, suitable for non-load-bearing osteochondral or soft tissue scaffolds. Biological evaluation per ISO 10993-5 and ISO 10993-6 is required because acidic degradation products from lactic acid can reduce local pH below 7.0 in confined bone cavities if the scaffold mass exceeds 100 mg/cm³ of defect volume. End product is a lyophilized, sterile porous scaffold supplied in double-peel pouches under nitrogen.

Thermoplastic Extrusion Requires Moisture Below 0.05 wt% to Protect Octreotide Acetate in Subcutaneous Rods

Hot-melt extrusion of RESOMER LC 703 S with octreotide acetate is performed on a co-rotating twin-screw extruder with 25:1 L/D, 11 mm screw diameter, and segmented screw elements configured with two kneading blocks to achieve distributive mixing without excessive shear. Granules and drug substance are pre-dried at 40 °C under vacuum for 24 h to a Karl Fischer moisture below 0.05 wt% before feeding. The polymer and drug are blended in a low-shear tumble mixer for 10 min, then fed at 0.5–1.0 kg/h into barrel zones set to 60 °C, 90 °C, 110 °C, 120 °C, and 115 °C at the die, with screw speed 80 rpm and melt pressure 20–35 bar. The extruded strand is cooled on a conveyor to 25 °C and pelletized to feed a micro-injection molding machine with 50 kN clamp force, producing rods of 1.0 mm diameter and 20 mm length. Drug content uniformity is analyzed per USP <905>, with acceptance values below 15 for a single dosage unit; dissolution is measured using USP Apparatus 4 in pH 7.4 phosphate-buffered saline at 37 °C, with a target release of 20–40% at 24 h and 70–90% at 7 days for a sustained-release profile. The main process conflict is the narrow processing window of ±5 °C around the die temperature: below 110 °C the melt viscosity rises beyond 1,200 Pa·s, causing high torque and drug degradation, while above 120 °C the caprolactone-rich phase separates and the rod becomes tacky. Residual lactide and caprolactone monomer are controlled to typical total values below 1.0% on the grade certificate of analysis, and the implant is evaluated per ISO 10993-5, ISO 10993-10, ISO 10993-11 for systemic toxicity, and USP <85> for endotoxin. End product is a sterile single-use implant rod for subcutaneous administration of peptide drugs over 1–3 months.